Food and Drug Administration

AstraZeneca (NYSE: AZN) spiked 1% this afternoon following rumors that Brilinta has received FDA approval. Benzinga then spoke with AstraZeneca, which said it had not yet received approval, but expected to soon. Moments later, the company announced that the FDA had now approved its anti-clotting...

By Brett Chase After a few months of blockbuster Food and Drug Administration advisory panel meetings, May seems a bit calmer. But there are certainly important dates for drug and biotechnolgy companies. Here are some events to watch for this month. Dates are subject to change. May 3 Vertex...

If Star Scientific's (NASDAQ: CIGX) press release is to be believed, we might be on the precipice of a genuine breakthrough. James Altucher took a moment to translate the confusing and unusually written press release into what he calls “Investor-English.” His conclusion is that Star Scientific has...

The research of Alzheimer's disease continues as new tests show great promise for the early diagnosis of the illness. According to the New York Times, the Food and Drug Administration will review a newly developed brain scan which purportedly can detect plaques indicative of Alzheimer's disease. A...

Arena Pharma (NASDAQ: ARNA) last price check is $1.89, down 7.35% after the announcement today; the completion of an end-of-review meeting with the US Food and Drug Administration (FDA) for the lorcaserin New Drug Application.

Shares of Incyte Corporation (Nasdaq: INCY) ended the day up 8.2% at $16.43 per share. Incyte Corporation reported after the market closed on Monday that its INCB18424 drug had a response rate of 42% in patients with myelofibrosis (MF), which caused its shares to start Tuesday trading significantly...

If you think that becoming a Food and Drug Administration consultant would be all food and no fun, think again. The FDA has been paying consultants millions of dollars for management help, including leadership classes held at a Civil War battlefield. However, as an agency that's supposed to be...

Shares of Savient Pharmaceuticals Inc (NASDAQ: SVNT) surged in pre-market trading after the approval of its gout drug by the Food and Drug Administration (FDA). SVNT's shares surged 23.31% to $18.20 in pre-market trading. The FDA has approved SVNT's gout drug for adults who were not getting any...

In something out of a science fiction movie, the Food and Drug Administration is considering allowing genetically modified salmon to be eaten by humans. Aqua Bounty is the first company being considered for approval, as the FDA wrote that modified fish are as safe to eat as regular fish. The...

Hapoalim Securities analyst Jon LeCroy reiterated his Buy rating for shares of Arena Pharmaceuticals Inc (Nasdaq: ARNA), with a price target of $6 per share. LeCroy said that Arena Pharmaceuticals (ARNA) presented two pooled analyses at the 2010 ADA meeting that showed that the company's lorcaserin...